• PCN31 COST OF CARE FOR MEDICARE PATIENTS DIAGNOSED WITH METASTATIC BREAST CANCER WHO RECEIVED TRASTUZUMAB

    May 1, 2009, 00:00

  • PND35 SOCIOECONOMIC FACTORS OF INSOMNIA PRESCRIPTION IN A NATIONAL DATABASE

    May 1, 2009, 00:00

  • CASE5 HARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT- A CASE STUDY OF ERLOTINIB AT A MAJOR CANCER CENTER

    May 1, 2009, 00:00

  • PMH59 THE IMPACT OF THE FDA ANTIDEPRESSANT BLACK BOX WARNING ON THE CONTINUITY OF ANTIDEPRESSANT TREATMENT IN CHILDREN WITH DEPRESSION

    May 1, 2009, 00:00

  • PUK11 AN ECONOMIC EVALUATION OF FESOTERODINE IN THE TREATMENT OF OVERACTIVE BLADDER (OAB) IN KOREA

    May 1, 2009, 00:00

  • DB4 COST OF DIABETIC-RELATED COMPLICATIONS AND CARDIOVASCULAR EVENTS BY TYPE OF EVENT AND SETTING ANNUALLY FOR THE FIRST THREE YEARS FOLLOWING ITS ONSET

    May 1, 2009, 00:00

  • PHP49 THE CHANGING DYNAMICS IN HEALTH CARE FUNDING

    May 1, 2009, 00:00

  • MS3 THE IMPACT OF COMPLIANCE WITH BIOLOGIC THERAPY ON CLINICAL OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS

    May 1, 2009, 00:00

  • PHP83 WHAT IS THE FUTURE IN THE IMPLEMENTATION OF HEALTH TECHNOLOGIES IN THE PUBLIC SECTOR IN SPAIN? A QUALITATIVE STUDY EXPLORING KEY DECISION-MAKERS PERSPECTIVES

    May 1, 2009, 00:00

  • PCV43 WHICH PUBLIC POLICY IS MORE COST-EFFECTIVE IN REDUCING CARDIAC DEATHS- INCREASED TAXES OR SMOKING BANS?

    May 1, 2009, 00:00

  • PHP38 THE POWER OF EPIDEMIOLOGICAL ESTIMATORS TO RATE INEQUALITIES IN HEALTH IN HIGH-INCOME OECD COUNTRIES, 1998-2002

    May 1, 2009, 00:00

  • PCV87 IS MEASURING HEALTH STATUS BENEFICIAL IN HEART FAILURE PATIENTS?

    May 1, 2009, 00:00

  • PIN33 COST EFFECTIVENESS OF SWITCHING TO SECOND LINE THERAPY WITH LOPINAVIR/RITONAVIR (LPV/R) IN KENYA

    May 1, 2009, 00:00

  • PIN36 THE ECONOMIC IMPACT OF MARAVIROC FOR ANTIRETROVIRAL TREATMENT-EXPERIENCED HIV-INFECTED INDIVIDUALS IN MEXICO

    May 1, 2009, 00:00

  • PMC30 USING AN ENCOUNTER-BASED DATABASE TO VALIDATE A DISEASE PROGRESSION MODEL- LESSONS FOR MODELERS

    May 1, 2009, 00:00

  • HT3 A FRAMEWORK FOR DERIVING A MINIMALLY ACCEPTABLE TARGET CLINICAL PROFILE AND A MAXIMUM VALUE-BASED PRICE FOR DRUGS IN DEVELOPMENT TO MEET HEALTH TECHNOLOGY ASSESSMENT REQUIREMENTS

    May 1, 2009, 00:00

  • PND38 EMPIRICAL CLASSIFICATION OF EPILEPSY TYPES IN INSURANCE CLAIMS DATA

    May 1, 2009, 00:00

  • PMH40 UNINTENDED CONSEQUENCES OF CURRENT ANTIDEPRESSANT USE IN A GERIATRIC POPULATION- DRUG-DRUG INTERACTIONS AND THEIR IMPLICATIONS FOR ADHERENCE

    May 1, 2009, 00:00

  • PIN54 INCREASING CHC TREATMENT RATE IN US IS A COST-SAVING STRATEGY

    May 1, 2009, 00:00

  • PMC66 USE OF THE MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW (M.I.N.I.) - VERSION 6 - IN AN INTERNATIONAL STUDY

    May 1, 2009, 00:00

  • PCASE2 THE HOSPITAL AS IMPORTANT SOURCE OF INFORMATION REGARDING CHARACTERISTICS OF HEALTH CARE USERS

    May 1, 2009, 00:00

  • PHP2 PHARMACY BENEFIT DESIGN AND PATIENT DRUG SUBSTITUTION

    May 1, 2009, 00:00

  • PDB26 RACE AND GENDER DIFFERENCES IN ECONOMIC BURDEN OF DIABETES HOSPITALIZATIONS IN TENNESSEE

    May 1, 2009, 00:00

  • PMH2 USE OF HYPNOTICS/ANXIOLYTICS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER- ASSOCIATIONS WITH CHRONIC PAIN, SLEEP DISORDERS, AND ANTIDEPRESSANT SELECTION

    May 1, 2009, 00:00

  • PMS58 FIBROMYALGIA- RUSSIAN RHEUMATOLOGISTS DISEASE MANAGEMENT

    May 1, 2009, 00:00

  • PCV44 COST EFFECTIVENESS OF CLOPIDOGREL TREATMENT VERSUS ASPIRIN TREATMENT IN SOUTH KOREAN PATIENTS WITH ATHEROTHROBOSIS- RESULTS OF THE CAPRIE (CLOPIDOGREL VERSUS ASPIRIN IN PATIENTS AT RISK OF ISCHEMIC EVENTS) STUDY

    May 1, 2009, 00:00

  • PSY49 DETERMINANTS OF MEDICAL SERVICES UTILIZATION IN CHRONIC NONCANCER PAIN PATIENTS

    May 1, 2009, 00:00

  • PIH5 AN ANALYSIS OF SELECT INJURY-INCREASING ANALGESIC MEDICATIONS IN MEDICARE DUAL ELIGIBLE ENROLLEES

    May 1, 2009, 00:00

  • PCV18 ADHERENCE TO STATIN TREATMENT AND ACHIEVING LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) GOALS IN AN EMPLOYEE POPULATION

    May 1, 2009, 00:00

  • CASE6 PILOT PROJECT- INTEGRATING ADMINISTRATIVE AND FINANCIAL DATABASES TO ESTIMATE PRICE OF HOSPITALIZATIONS

    May 1, 2009, 00:00

  • HM3 IMPACT OF A SPECIALTY CARE MANAGEMENT PROGRAM ON MEDICATION ADHERENCE AND HEALTH CARE UTILIZATION AMONG NON-ELDERLY ADULTS WITH MULTIPLE SCLEROSIS

    May 1, 2009, 00:00

  • PIH32 THE BRAZILIAN PORTUGUESE VALIDATION OF THE PROLAPSE-QUALITY OF LIFE QUESTIONNAIRE-P-QOL

    May 1, 2009, 00:00

  • PHP16 MARKET DISCONTINUATION OF PHARMACEUTICALS IN THE UNITED STATES- ANALYSIS OF DRUGS APPROVED BY THE FDA FROM 1939 TO 2008

    May 1, 2009, 00:00

  • PDB33 DAILY AVERAGE CONSUMPTION OF BASAL INSULIN IN PATIENTS WITH TYPE 2 DIABETES

    May 1, 2009, 00:00

  • PSY13 FREQUENCY AND BOTHERSOMENESS OF SIDE EFFECTS IN PAIN PATIENTS TAKING OXYCODONE IMMEDIATE RELEASE- IMPACT ON PRESCRIPTION AND OVER-THE-COUNTER MEDICATION USE

    May 1, 2009, 00:00

  • CM3 THE IMPACT OF MEDICARE PART D ON ELDERLY PATIENTS COMPLIANCE WITH STATINS

    May 1, 2009, 00:00

  • PM2 IMPACT OF PHARMACOGENETICS ON THE COSTS OF MANAGING ADVERSE EVENTS WITH WARFARIN- A PROSPECTIVE ANALYSIS

    May 1, 2009, 00:00

  • PCN73 USING SHORT-TERM RESPONSE TO PREDICT LONG-TERM OUTCOMES IN PATIENTS WITH IMATINIB-RESISTENT OR IMATINIB-INTOLERANT CHRONIC MYELOID LEUKAEMIA

    May 1, 2009, 00:00

  • PIH45 THE IMPACT OF MEDICARE PART D ON HEALTH CARE UTILIZATION AND HEALTH OUTCOMES FOR MEDICARE BENEFICIARIES WITHOUT PREVIOUS DRUG COVERAGE

    May 1, 2009, 00:00

  • PCV3 MEDIATING ROLE OF CEREBROVASCULAR DISEASE IN THE ASSOCIATION BETWEEN DIABETES MELLITUS AND DEMENTIA

    May 1, 2009, 00:00

  • PMC62 ASSESSING THE QUALITY OF CONJOINT ANALYSIS APPLICATIONS IN HEALTH- A PILOT EVALUATION OF THE ISPOR CHECKLIST FOR GOOD RESEARCH PRACTICE IN CONJOINT ANALYSIS

    May 1, 2009, 00:00

  • PMH30 HOSPITALIZATION COSTS FOR SCHIZOPHRENIA RELAPSES IN A PUBLIC PSYCHIATRIC INSTITUTION

    May 1, 2009, 00:00

  • PND34 DISEASE BURDEN AND TREATMENT PATTERNS OF PARKINSONS DISEASE IN A LONG TERM CARE SETTING

    May 1, 2009, 00:00

  • PCV92 HOW DOES THE OUT-OF-POCKET PAYMENT MATTER TO HYPERTENSIVE PATIENTS CHOICES OF ACCESSING DIFFERENT MEDICAL FACILITIES IN TAIWAN? THE PRELIMINARY STUDY OF A DISCRETE CHOICE EXPERIMENT

    May 1, 2009, 00:00

  • PCN13 THE PREVALENCE AND COSTS OF ADVERSE METABOLIC EFFECTS OF ATYPICAL ANTIPSYCHOTICS IN SCHIZOPHRENIC PATIENTS

    May 1, 2009, 00:00

  • PCN66 COST OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY AMONG U.S. BREAST CANCER PATIENTS

    May 1, 2009, 00:00

  • PMC4 A FRAMEWORK FOR DEVELOPING A FLEXIBLE CONTROL-BASED ASTHMA POLICY MODEL

    May 1, 2009, 00:00

  • PHP59 INCIDENCE AND OUTCOMES OF POTENTIAL DRUG-DRUG INTERACTIONS AMONG MEDICARE PART D PATIENTS

    May 1, 2009, 00:00

  • PRS41 APPROPRIATE USE OF INHALED CORTICOSTEROID AND LONG-ACTING -AGONIST COMBINATION THERAPY AMONG ASTHMA PATIENTS

    May 1, 2009, 00:00

  • PCN45 PHARMACOECONOMIC EVALUATION OF THE USE OF SOMATOSTATIN ANALOGS HANDLING THE ASSOCIATED SYMPTOMS OF CARCINOID SYNDROME

    May 1, 2009, 00:00

  • PMC24 A PREDICTION MODEL TO IDENTIFY SUBJECTS WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC) FROM A MANAGED CARE ADMINISTRATIVE CLAIMS DATABASE

    May 1, 2009, 00:00

  • PCV63 INPATIENT BURDEN OF ILLNESS AND PREDICTORS OF CHARGES OR LENGTHS OF STAY AMONG ADULT HEART TRANSPLANTATION PATIENTS

    May 1, 2009, 00:00

  • PMS18 ESTIMATION OF COSTS RELATED TO ADVERSE EVENTS IN NSAID TREATMENT OF OSTEOARTHRITIS - A COMPARISON BETWEEN CELECOXIB AND IBUPROFEN USING A VALIDATED MODEL

    May 1, 2009, 00:00

  • PCN40 A COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE AT A TERTIARY CANCER CENTER

    May 1, 2009, 00:00

  • FD3 CONCEPTUAL ISSUES IN THE DEVELOPMENT OF A MEASURE OF FORMULARY CULTURE

    May 1, 2009, 00:00

  • PMC57 RELATIONSHIP BETWEEN QUALITY OF LIFE AND HEALTH-RELATED MEASURES INCLUDING SYMPTOMS, BIOCHEMICAL MARKERS AND TUMOR BURDEN

    May 1, 2009, 00:00

  • PMC88 AN EXPLORATORY ANALYSIS OF REASONS BEHIND PREMATURE TERMINATION OF RANDOMIZED CONTROLLED TRIALS

    May 1, 2009, 00:00

  • PRS45 SMOKING-ATTRIBUTABLE BURDEN OF FOUR TOBACCO-RELATED DISEASES IN COLOMBIA IN 2007

    May 1, 2009, 00:00

  • PMH5 PATIENT ASSESSED QUALITY OF LIFE VERSUS CLINICIAN ASSESSMENT- A POST-HOC ANALYSIS OF A TRIAL OF ARIPIPRAZOLE IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA

    May 1, 2009, 00:00

  • PMS33 BURDEN OF ILLNESS OF CONSERVATIVE MEDICAL MANAGEMENT OF OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURES IN JAPAN

    May 1, 2009, 00:00

  • PCV95 ELECTRONIC MEDICAL RECORD USE AND WARFARIN DRUG-DRUG INTERACTIONS DURING AMBULATORY VISITS IN THE UNITED STATES, 2003-2006

    May 1, 2009, 00:00

  • PCN64 THE ECONOMIC BURDEN ASSOCIATED WITH METASTATIC COLORECTAL CANCER

    May 1, 2009, 00:00

  • PMC42 FINITE MIXTURE REGRESSIONS IN MODELING PRESCRIPTION DRUG UTILIZATION AND PRESCRIPTION DRUG EXPENDITURES OF PATIENTS WITH REUMATOID ARTHRITIS (RA)

    May 1, 2009, 00:00

  • PND9 IS GENETIC TESTING IN COMBINATION WITH PREVENTIVE DONEPEZIL (ARICEPT) TREATMENT FOR PATIENTS WITH MILD COGNITIVE IMPAIRMENT COST- EFFECTIVE?

    May 1, 2009, 00:00

  • PCN39 COST-EFFECTIVENESS ANALYSIS OF LUNG CANCER SCREENING WITH COMPUTED TOMOGRAPHY

    May 1, 2009, 00:00

  • PIN49 NEW ANTIFUNGAL MEDICATION IMPACT ON MARKET SHARE AND UTILIZATION OF TRADITIONAL AGENTS IN A SINGLE HEALTH CARE SYSTEM

    May 1, 2009, 00:00

  • PMC21 DOES VARYING SELECTION BIAS CORRECTION TECHNIQUE MATTER IN ESTIMATION OF TREATMENT EFFECTS IN PRESENCE OF MULTIPLE ENDOGENOUS TREATMENTS?

    May 1, 2009, 00:00

  • PIN35 COST-EFFECTIVENESS OF MARAVIROC FOR HIV IN MEXICO

    May 1, 2009, 00:00

  • PND30 DATA ANALYSIS OF PEDIATRIC INPATIENTS DIAGNOSED WITH BRAIN ABSCESS

    May 1, 2009, 00:00

  • PMC11 GROWTH, CHARACTERISTICS AND QUALITY OF THE COST-UTILITY ANALYSIS LITERATURE THROUGH 2006

    May 1, 2009, 00:00

  • PCN1 TIME DELAY OF OCCURRENCE OF SECONDARY MALIGNANT TUMORS AFTER PRIMARY BREAST CANCER IN THE FEMALE POPULATION OF HUNGARY BETWEEN 2003 AND 2007

    May 1, 2009, 00:00

  • PC4V19 EFFECT OF ACE INHIBITORS/ARBS AND STATINS ON THE INCIDENCE OF DEMENTIA, IN PATIENTS WITH CHRONIC HEART FAILURE

    May 1, 2009, 00:00

  • CASE4 DIABETES PHYSICIAN RECOGNITION IN A LARGE HEALTH PLAN

    May 1, 2009, 00:00

  • PSS3 USING 'NUMBER NEEDED TO TREAT' TO HELP CONCEPTUALIZE THE MAGNITUDE OF BENEFIT AND RISK OF TNF INHIBITORS FOR PATIENTS WITH SEVERE PSORIASIS

    May 1, 2009, 00:00

  • PMC56 THE EFFECT OF RECALL PERIOD ON CANCER PATIENTS RATINGS OF THE SEVERITY OF MULTIPLE SYMPTOMS

    May 1, 2009, 00:00

  • PHC7 DEVELOPMENT AND VALIDATION OF SPECIFIC HEALTH RELATED QUALITY OF LIFE QUESTIONNAIRE FOR HALITOSIS- THE HALITOSIS QUALITY OF LIFE QUESTIONNAIRE (HQLQ)

    May 1, 2009, 00:00

  • PIN6 A DATA ANALYSIS OF INPATIENTS AFFECTED BY THE HUMAN PAPILLOMAVIRUS

    May 1, 2009, 00:00

  • PRS6 ESTIMATION OF QUALITY-ADJUSTED LIFE EXPECTANCY AND LOSS OF UTILITY IN PATIENTS UNDER PROLONGED MECHANICAL VENTILATION

    May 1, 2009, 00:00

  • PCN70 MODELLING THE COST EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES VERSUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES IN METASTATIC COLORECTAL CANCER PATIENTS IN SWED ...

    May 1, 2009, 00:00

  • PDB12 RISK FACTORS FOR DEMENTIA IN ELDERLY PATIENTS WITH DIABETES MELLITUS

    May 1, 2009, 00:00

  • PHP26 THE IMPACT OF MEDICARE PART D ON MEDICARE-MEDICAID DUAL-ELIGIBLE BENEFICIARIES PRESCRIPTION UTILIZATION AND EXPENDITURES

    May 1, 2009, 00:00

  • PMC70 VALUING HEALTH FROM SCRATCH- THE APPLICATION OF COMMONSENSE PRINCIPLES TO THE DESIGN OF HEALTH STATE VALUATION METHODS

    May 1, 2009, 00:00

  • PHP84 A COMPARISON OF REASONS FOR RECOMMENDATION AND REJECTION ACROSS FOUR HEALTH TECHNOLOGY APPRAISAL SYSTEMS CATEGORISED BY DISEASE

    May 1, 2009, 00:00

  • PCN62 FIRST YEAR COST EXPENDITURES ASSOCIATED WITH HEAD AND NECK CANCER DIAGNOSIS IN THE U.S. MANAGED CARE POPULATION

    May 1, 2009, 00:00

  • PSY43 USE OF PRESCRIPTION PHARMACOTHERAPY IN PATIENTS WITH FIBROMYALGIA - EVIDENCE OF UNMET NEEDS?

    May 1, 2009, 00:00

  • CV1 COMPARISON OF CARDIOVASCULAR EVENT RATES IN SUBJECTS WITH TYPE-2 DIABETES MELLITUS WHO AUGMENTED FROM STATIN MONOTHERAPY TO STATIN PLUS FIBRATE COMBINATION THERAPY WITH THOSE WHO REMAINED ON STATIN MONOTHERAPY

    May 1, 2009, 00:00

  • PIH10 COST EFFECTIVENESS OF ORAL BISPHOSPHONATES ADMINISTERED ON EXTENDED DOSING INTERVALS

    May 1, 2009, 00:00

  • PUK13 COST-EFFECTIVENESS OF A RENAL HEALTH PROGRAM IN PATIENTS WITH HYPERTENSIVE AND/OR DIABETES INDUCED CHRONIC KIDNEY DISEASE

    May 1, 2009, 00:00

  • PHP82 USE OF INDIRECT COMPARISON IN HTA SUBMISSIONS

    May 1, 2009, 00:00

  • PSY29 VARIABILITY OF FEES IN THE FIELD OF HAEMOGRAMS IN THE AUSTRIAN CONTRACT PHYSICIANS SECTOR

    May 1, 2009, 00:00

  • PDB17 GLYCEMIC VARIABILITY AND COMPLICATIONS IN PATIENTS WITH DIABETES MELLITUS- EVIDENCE FROM A SYSTEMATIC REVIEW OF THE LITERATURE

    May 1, 2009, 00:00

  • PND42 BRAZILIAN NATIONAL GUIDELINE FOR MULTIPLE SCLEROSIS (MS)- AN EXPLORATORY STUDY ABOUT THE IMPACT OF THE PATIENTS ADHERENCE IN THE TREATMENT COSTS

    May 1, 2009, 00:00

  • PIH4 PERSONALIZED MEDICINE- TRENDS IN CLINICAL STUDIES BASED ON NATIONAL REGISTRY DATA

    May 1, 2009, 00:00

  • PCV91 DISPARITIES IN CORONARY ARTERY DISEASE CARE AMONG ENROLLEES WITH AARP MEDICARE SUPPLEMENT INSURANCE

    May 1, 2009, 00:00

  • DU3 PATTERN OF UTILIZATION OF PEGFILGRASTIM IN PATIENTS WITH CHEMOTHERAPY-INDUCED NEUTROPENIA- A RETROSPECTIVE ANALYSIS OF ADMINISTRATIVE CLAIMS DATA

    May 1, 2009, 00:00

  • PSS16 CHARACTERIZING FUNCTIONAL LIMITATIONS FOR ADULTS WITH DIABETIC RETINOPATHY

    May 1, 2009, 00:00

  • PCN68 COST-EFFECTIVENESS OF CETUXIMAB (ERBITUXTM) FOR THE FIRST LINE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN CANADA

    May 1, 2009, 00:00

  • PIH39 ASSOCIATION BETWEEN SEXUAL DRIVE CHANGE AND PREMENSTRUAL SYMPTOMS

    May 1, 2009, 00:00

  • PCV109 THERAPY INTERRUPTIONS IN PATIENTS SWITCHED FROM BRANDED TO OTHER GENERIC STATINS

    May 1, 2009, 00:00

  • PMH72 IMPACT OF PHARMACY BENEFIT DESIGN ON ANTI-PSYCHOTIC MEDICATION ADHERENCE AND DISCONTINUATION

    May 1, 2009, 00:00

  • PMH84 AN ASSESSMENT OF THE IMPACT OF AN EDUCATIONAL PHARMACY MANAGEMENT INTERVENTION ON PRESCRIBERS TO MEDICAID BENEFICIARIES

    May 1, 2009, 00:00

  • PCV77 EVALUATION OF AN EDUCATIONAL ANTIHYPERTENSIVE MEDICATION ADHERENCE TOOL- IMPACT ON ANTIHYPERTENSIVE ADHERENCE AND BLOOD PRESSURE CONTROL

    May 1, 2009, 00:00

  • PIH37 URINARY URGENCY INTENSITY RATING IN RELATION TO SYMPTOM FREQUENCY, BOTHER, AND TREATMENT SEEKING- RESULTS FROM EPILUTS IN THE US, UK, AND SWEDEN (SE)

    May 1, 2009, 00:00

  • PIN45 EMPLOYEES WILLINGNESS TO PAY FOR INFLUENZA VACCINATION OF HOUSEHOLD MEMBERS-RESULTS FROM THE CHILD AND HOUSEHOLD INFLUENZA-ILLNESS AND EMPLOYEE FUNCTION (CHIEF) STUDY

    May 1, 2009, 00:00

  • PRS35 PREVALENCE OF ASTHMA, DIABETES MELLITUS AND ESSENTIAL HYPERTENSION AND ASSOCIATION OF HEALTH INSURANCE WITH BRAND STATUS OF DIAGNOSIS SPECIFIC PRESCRIPTION DRUGS

    May 1, 2009, 00:00

  • PCN90 A METHODOLOGICAL INVESTIGATION TO DEFINE A CLINICALLY RELEVANT CUT-OFF POINT IN THE ORDINAL SCALE OF THE EORTC QLQ-C30 QUESTIONNAIRE

    May 1, 2009, 00:00

  • PMH26 THE COST BURDEN OF TREATMENT RESISTANCE IN PATIENTS WITH DEPRESSION

    May 1, 2009, 00:00

  • Prescribing Trends and Drug Budget Impact of the ARBs in the UK

    Mar 1, 2009, 00:00

  • FDAMA 1997 Section 114- Another Look

    Mar 1, 2009, 00:00

  • Who Does the Numbers? The Role of Third-Party Technology Assessment to Inform Health Systems' Decision-Making about the Funding of Health Technologies

    Mar 1, 2009, 00:00

  • What Ever Happened to FDAMA Section 114? A Look back after 10 Years

    Mar 1, 2009, 00:00

  • Cost-Effectiveness of Primary versus Secondary Prophylaxis with Pegfilgrastim in Women with Early-Stage Breast Cancer Receiving Chemotherapy

    Mar 1, 2009, 00:00

  • The Costs of Care in Atrial Fibrillation and the Effect of Treatment Modalities in Germany

    Mar 1, 2009, 00:00

  • Cost Impact of Diagnostic Imaging for Lower Extremity Peripheral Vascular Occlusive Disease

    Mar 1, 2009, 00:00

  • QALYs- Some Challenges

    Mar 1, 2009, 00:00

  • Economic Evaluation of the Decisions of the Israeli Public Committee for Updating the National List of Health Services in 2006/2007

    Mar 1, 2009, 00:00

  • Economic Evaluation of Influenza Pandemic Mitigation Strategies in the United States Using a Stochastic Microsimulation Transmission Model

    Mar 1, 2009, 00:00

  • A Different Approach to Health State Valuation

    Mar 1, 2009, 00:00

  • A Cost-Effectiveness Model Comparing Endovascular Repair to Open Surgical Repair of Abdominal Aortic Aneurysms in Canada

    Mar 1, 2009, 00:00

  • Editorial- Moving the QALY Forward or Just Stuck in Traffic?

    Mar 1, 2009, 00:00

  • Excessive Hospitalizations and Its Associated Economic Burden among People with Diabetes in the United States

    Mar 1, 2009, 00:00

  • The Health and Economic Consequences of Moderate Alcohol Consumption in Germany 2002

    Mar 1, 2009, 00:00

  • Information on Center Characteristics as Costs' Determinants in Multicenter Clinical Trials- Is Modeling Center Effect Worth the Effort?

    Mar 1, 2009, 00:00

  • What Outcomes Are Important to Patients with Long Term Conditions? A Discrete Choice Experiment

    Mar 1, 2009, 00:00

  • Retaining, and Enhancing, the QALY

    Mar 1, 2009, 00:00

  • Cost Analysis of Long-Term Treatment of Patients with Symptomatic Gastroesophageal Reflux Disease (GERD) with Esomeprazole On-Demand Treatment or Esomeprazole Continuous Treatment- An Open, Randomized, Multicenter Study in Switzerland

    Mar 1, 2009, 00:00

  • Moving the QALY Forward- Rationale for Change

    Mar 1, 2009, 00:00

  • Cost-Effectiveness of Testing for Breast Cancer Susceptibility Genes

    Mar 1, 2009, 00:00

  • Mapping the English and Chinese Versions of the Functional Assessment of Cancer Therapy–General to the EQ-5D Utility Index

    Mar 1, 2009, 00:00

  • Predicting the Short Form-6D Preference-Based Index Using the Eight Mean Short Form-36 Health Dimension Scores- Estimating Preference-Based Health-Related Utilities When Patient Level Data Are not Available

    Mar 1, 2009, 00:00

  • Comparing the Health Utilities Index Mark 3 (HUI3) with the Short Form-36 Preference-Based SF-6D in Chronic Kidney Disease

    Mar 1, 2009, 00:00

  • Editorial- On the Benefits of Modeling Using QALYs for Societal Resource Allocation- The Model Is the Message

    Mar 1, 2009, 00:00

  • A Longitudinal Evaluation of Health-Related Quality of Life of Patients with Parkinson's Disease

    Mar 1, 2009, 00:00

  • Further Validation and Responsiveness Assessment of the Herpes Outbreak Impact Questionnaire and Herpes Symptom Checklist

    Mar 1, 2009, 00:00

  • The Costs of Change- Direct Medical Costs of Solid Organ Transplantation in British Columbia, Canada, 1995–2003

    Mar 1, 2009, 00:00

  • Modeling Length of Stay in Hospital and Other Right Skewed Data- Comparison of Phase-Type, Gamma and Log-Normal Distributions

    Mar 1, 2009, 00:00

  • Value of Information and Value of Implementation- Application of an Analytic Framework to Inform Resource Allocation Decisions in Metastatic Hormone-Refractory Prostate Cancer

    Mar 1, 2009, 00:00

  • QALYs- The Basics

    Mar 1, 2009, 00:00

  • Does Attribute Framing in Discrete Choice Experiments Influence Willingness to Pay? Results from a Discrete Choice Experiment in Screening for Colorectal Cancer

    Mar 1, 2009, 00:00

  • Cost-Effectiveness Evaluation of Ertapenem versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections Accounting for Antibiotic Resistance

    Mar 1, 2009, 00:00

  • Cross-Cultural Validation of the Scales for Outcomes in Parkinson's Disease-Psychosocial Questionnaire (SCOPA-PS) in Four Latin American Countries

    Mar 1, 2009, 00:00

  • Toward a Consensus on the QALY

    Mar 1, 2009, 00:00

  • Health Utilities in Patients with HIV/AIDS in Thailand

    Mar 1, 2009, 00:00

  • The Use of QALYs in Clinical and Patient Decision-Making- Issues and Prospects

    Mar 1, 2009, 00:00

  • Mapping Utility Scores from a Disease-Specific Quality-of-Life Measure in Bariatric Surgery Patients

    Mar 1, 2009, 00:00

  • Development of a New Questionnaire to Assess Patient Perceptions of Cancer-Related Fatigue- Item Generation and Item Reduction

    Jan 1, 2009, 00:00

  • Evaluation of an Internet-Based Disease Trajectory Decision Tool for Prostate Cancer Screening

    Jan 1, 2009, 00:00

  • Validation of Gastrointestinal Quality of Life Index in Swedish for Assessing the Impact of Gallstones on Health-Related Quality of Life

    Jan 1, 2009, 00:00

  • The Health Value and Cost of Care for Major Depression

    Jan 1, 2009, 00:00

  • Cost-Effectiveness of Treatments Reducing Coronary Heart Disease Mortality in Ireland, 2000 to 2010

    Jan 1, 2009, 00:00

  • Breaking the Silence- Exploring the Potential Effects of Explicit Instructions on Incorporating Income and Leisure in TTO Exercises

    Jan 1, 2009, 00:00

  • Utility Estimates for Decision–Analytic Modeling in Chronic Heart Failure—Health States Based on New York Heart Association Classes and Number of Rehospitalizations

    Jan 1, 2009, 00:00

  • The Effects of Laparoscopic Surgery and Nosocomial Infections on the Cost of Care- Evidence from Three Common Surgical Procedures

    Jan 1, 2009, 00:00

  • An Empiric Estimate of the Value of Life- Updating the Renal Dialysis Cost-Effectiveness Standard

    Jan 1, 2009, 00:00

  • Budgetary Impact of Varenicline in Smoking Cessation in the United Kingdom

    Jan 1, 2009, 00:00

  • Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy—Prostate- Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer

    Jan 1, 2009, 00:00

  • Using Conjoint Analysis to Estimate Healthy-Year Equivalents for Acute Conditions- An Application to Vasomotor Symptoms

    Jan 1, 2009, 00:00

  • The Development of the Herpes Symptom Checklist and the Herpes Outbreak Impact Questionnaire

    Jan 1, 2009, 00:00

  • Reliability of the Discrete Choice Experiment at the Input and Output Level in Patients with Rheumatoid Arthritis

    Jan 1, 2009, 00:00

  • Prevention and Management of Hyperphosphatemia with Sevelamer in Canada- Health and Economic Consequences

    Jan 1, 2009, 00:00

  • Satisfaction and Adherence in Patients with Iron Overload Receiving Iron Chelation Therapy as Assessed by a Newly Developed Patient Instrument

    Jan 1, 2009, 00:00

  • Mapping the EORTC QLQ C-30 onto the EQ-5D Instrument- The Potential to Estimate QALYs without Generic Preference Data

    Jan 1, 2009, 00:00

  • Potential for Cost-Savings in the Care of Hospitalized Low-Risk Community-Acquired Pneumonia Patients in China

    Jan 1, 2009, 00:00

  • Estimating a Preference-Based Single Index from the Overactive Bladder Questionnaire

    Jan 1, 2009, 00:00

  • Long-Term Cost-Effectiveness of Pioglitazone versus Placebo in Addition to Existing Diabetes Treatment- A US Analysis Based on PROactive

    Jan 1, 2009, 00:00

  • Development and Evaluation of the Adherence to Refills and Medications Scale (ARMS) among Low-Literacy Patients with Chronic Disease

    Jan 1, 2009, 00:00

  • ISPOR Code of Ethics

    Jan 1, 2009, 00:00

  • Deterministic Sensitivity Analysis for First-Order Monte Carlo Simulations- A Technical Note

    Jan 1, 2009, 00:00

  • Gaining Efficiencies- Resources and Demand for Dialysis around the Globe

    Jan 1, 2009, 00:00

  • The Burden of Migraine in the United States- Current and Emerging Perspectives on Disease Management and Economic Analysis

    Jan 1, 2009, 00:00

  • Health State Valuation Methods and Reference Points- The Case of Tinnitus

    Jan 1, 2009, 00:00

  • Ultrasound-Guided Central Line Placement as Compared with Standard Landmark Technique- Some Unpleasant Arithmetic for the Economics of Medical Innovation

    Jan 1, 2009, 00:00

  • The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer

    Jan 1, 2009, 00:00

  • The Impact of Proton Pump Inhibitor Compliance on Health-Care Resource Utilization and Costs in Patients with Gastroesophageal Reflux Disease

    Jan 1, 2009, 00:00

  • Economic Valuation of Informal Care- Conjoint Analysis Applied in a Heterogeneous Population of Informal Caregivers

    Dec 1, 2008, 00:00

  • Health State Utilities in Latent and Active Tuberculosis

    Dec 1, 2008, 00:00

  • Health State Utility Scores for Cancer-Related Anemia through Societal and Patient Valuations

    Dec 1, 2008, 00:00

  • Psychometric Equivalence of the OAB-q in Danish, German, Polish, Swedish, and Turkish

    Dec 1, 2008, 00:00

  • Estimation of Life Expectancy and the Expected Years of Life Lost in Patients with Major Cancers- Extrapolation of Survival Curves under High-Censored Rates

    Dec 1, 2008, 00:00

  • Reductions in Human Papillomavirus-Disease Resource Use and Costs with Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccination- The FUTURE Study Economic Evaluation

    Dec 1, 2008, 00:00

  • Expected Value of Perfect Information- An Empirical Example of Reducing Decision Uncertainty by Conducting Additional Research

    Dec 1, 2008, 00:00

  • Cost-Effectiveness of a Low-Calorie Diet and Orlistat for Obese Persons- Modeling Long-Term Health Gains through Prevention of Obesity-Related Chronic Diseases

    Dec 1, 2008, 00:00

  • Willingness to Accept versus Willingness to Pay in a Discrete Choice Experiment

    Dec 1, 2008, 00:00

  • Sociodemographic and Clinical Correlates of Utility Scores in Alzheimer's Disease

    Dec 1, 2008, 00:00

  • Reviewer Acknowledgment

    Dec 1, 2008, 00:00

  • A Predictive Model of Health State Utilities for HIV Patients in the Modern Era of Highly Active Antiretroviral Therapy

    Dec 1, 2008, 00:00

  • “Price Management” and Its Impact on Hospital Pharmaceutical Expenditure and the Availability of Medicines in New Zealand Hospitals

    Dec 1, 2008, 00:00

  • Citizen's Preferences Regarding Principles to Guide Health-Care Allocation Decisions in Thailand

    Dec 1, 2008, 00:00

  • Hispanic Valuation of the EQ-5D Health States- A Social Value Set for Latin Americans

    Dec 1, 2008, 00:00

  • Deriving an Algorithm to Convert the Eight Mean SF-36 Dimension Scores into a Mean EQ-5D Preference-Based Score from Published Studies (Where Patient Level Data Are Not Available)

    Dec 1, 2008, 00:00

  • Balancing Equity and Efficiency in Health Priorities in Ghana- The Use of Multicriteria Decision Analysis

    Dec 1, 2008, 00:00

  • Drotrecogin Alfa's Impact on Intensive Care Workload in Real Life Practice- A Propensity Score Approach

    Dec 1, 2008, 00:00

  • Cost-Effectiveness of Preventing Hip Fractures by Hip Protectors in Elderly Institutionalized Residents in Germany

    Dec 1, 2008, 00:00

  • Discrete-Event Simulation Applied to Analysis of Waiting Lists. Evaluation of a Prioritization System for Cataract Surgery

    Dec 1, 2008, 00:00

  • Validity of the EuroQoL (EQ-5D) Instrument in a Greek General Population

    Dec 1, 2008, 00:00

  • Estimating Quality Weights for EQ-5D Health States with the Time Trade-Off Method in South Korea

    Dec 1, 2008, 00:00

  • Factors Associated with Variation in Utility Scores among Patients with Prostate Cancer

    Dec 1, 2008, 00:00

  • The Cost-Effectiveness of Atypicals in the UK

    Dec 1, 2008, 00:00

  • Statin Cost-Effectiveness Comparisons Using Real-World Effectiveness Data- Formulary Implications

    Dec 1, 2008, 00:00

  • PRS27 INTERPRETING SCORES ON THREE PATIENT-REPORTED OUTCOME MEASURES FOR ASTHMA

    Nov 1, 2008, 00:00

  • PCV118 ADVANCING SYNCOPE DIAGNOSISTHROUGH IMPLANTABLE LOOP RECORDERS (ILRS) IN SWEDEN- COST-EFFECTIVENESS ANALYSIS OF NEW DIAGNOSTIC STRATEGIES

    Nov 1, 2008, 00:00

  • PDB57 EFFECT OF INSULIN GLARGINE OR NPH INSULIN ON TREATMENT SATISFACTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Nov 1, 2008, 00:00

  • PDB54 PSYCHOLOGICAL INSULIN RESISTANCE (PIR)- PATIENT AND PHYSICIAN BELIEFS IMPACTING DIABETES MANAGEMENT

    Nov 1, 2008, 00:00

  • PRS24 QUALITY OF LIFE RESULTS USING THE EUROQOL QUESTIONNAIRES AND DIRECT MEDICAL COSTS IN ASTHMATIC PATIENTS. CHAS STUDY

    Nov 1, 2008, 00:00

  • PIN37 GENITAL WARTS IN ITALY- A COST OF ILLNESS ANALYSIS

    Nov 1, 2008, 00:00

  • PHP9 DELAY OF DECISION-MAKING ON PHARMACEUTICAL REIMBURSEMENT IN NORMAL PROCEDURE IN HUNGARY

    Nov 1, 2008, 00:00

  • PG132 CORRELATION BETWEENTHE SEVERITY OF UPPER GASTROINTESTINAL (GI) SYMPTOMS AND ENDOSCOPIC FINDINGS IN THE GREEK PRIMARY CARE SETTING

    Nov 1, 2008, 00:00

  • PSS28 VENOUS LEG ULCER. COSTS-OF-ILLNESS OF IN GERMANY. A NATIONAL CROSS-SECTIONAL STUDY

    Nov 1, 2008, 00:00

  • PIN36 SOCIO-ECONOMIC IMPACT OF AVIAN INFLUENZA IN SOUTH-EAST ASIA AND NEIGHBOURING HIGH RISK COUNTRIES

    Nov 1, 2008, 00:00

  • CN3 COST OF INITIAL PROSTATE CANCERTREATMENT FOLLOWING DIAGNOSIS PER PATIENT BY STAGE- ESTIMATES FROM THE UK, FRANCE, GERMANY, ITALY AND SPAIN

    Nov 1, 2008, 00:00

  • PCV35 COST-EFFECTIVENESS ANALYSIS OF STROKE REHABILITATION STRATEGIES IN EASTERN CHINA

    Nov 1, 2008, 00:00

  • PG140 PROTON PUMP INHIBITORS MARKET IN PRIMARY CARE SETTING

    Nov 1, 2008, 00:00

  • MH5 EFFECT OF A NURSE TELEPHONE FOLLOW-UP ON THERAPEUTIC ADHERENCE OF PATIENTS WITH SCHIZOPHRENIA

    Nov 1, 2008, 00:00

  • PMS7 PREVALENCE OF FIBROMYALGIA- A LARGE-SCALE EUROPEAN SURVEY- EARLY RESULTS IN UNITED-KINGDOM

    Nov 1, 2008, 00:00

  • PCN106 PROSTATE CANCER DIAGNOSIS IN SPAIN- HOW IS IT PERFORMED? HOW MUCH DOES IT COST FOR SPANISH NHS?

    Nov 1, 2008, 00:00

  • PIH8 COST-EFFECTIVENESS OF PLANNED CAESAREAN SECTION VERSUS PLANNEDVAGINAL DELIVERY IN BREECH-PRESENTATION PREGNANCIES AT TERM

    Nov 1, 2008, 00:00

  • IN4 ACHIEVING SUSTAINED VIROLOGIC RESPONSE WITH CHRONIC HEPATITIS CTREATMENT IS ASSOCIATED WITH IMMEDIATE HEALTH CARE UTILIZATION BENEFITS IN EUROPE

    Nov 1, 2008, 00:00

  • PMS54 RELIEF OF PAIN AND SYMPTOMS IN KNEE CARTILAGE DEFECT IS ASSOCIATED WITH HIGHER SF-36 UTILITY SCORES- DATA FROM A PROSPECTIVE RANDOMIZED TRIAL OF CHONDROCELECT

    Nov 1, 2008, 00:00

  • PCN26 A COST-EFFECTIVENESS ANALYSIS OF XELOX AND FOLFOX-4 COMBINED WITH OR WITHOUT BEVACIZUMAB FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN

    Nov 1, 2008, 00:00

  • PSS11 SENSITIVE SKINS IN FRANCE- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PCV41 COST EFFECTIVENESS OF IMPLANTABLE LOOP RECORDER SYSTEM (REVEAL DX) FROM THE SPANISH NHS PERSPECTIVE

    Nov 1, 2008, 00:00

  • PDB19 ESTIMATING THE COST EFFECTIVENESS IN THE UK OF VILDAGLIPTIN COMPARED TO PIOGLITAZONE AS ADD-ON THERAPY TO METFORMIN USING THE SHEFFIELD TYPE 2 DIABETES MODEL

    Nov 1, 2008, 00:00

  • PDB31 THE COST OF TYPE 2 DIABETES MELLITUS IN CZECH REPUBLIC

    Nov 1, 2008, 00:00

  • HT2 UPDATE OF RESULTS AND OUTCOMES OF NICE SINGLE TECHNOLOGY APPRAISALS-ECONOMIC CRITICISMS

    Nov 1, 2008, 00:00

  • PG16 THE MANAGEMENT OF GASTRO OESOPHAGEAL REFLUX DISEASE IN SPAIN- A BUDGET IMPACT ANALYSIS TO ESTIMATE COSTS DUETO A GREATER PANTOPRAZOL IV PENETRATION

    Nov 1, 2008, 00:00

  • PSS41 USTEKINUMAB SIGNIFICANTLY IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS

    Nov 1, 2008, 00:00

  • PMC56 THE TRANSFERABILITY OF ECONOMIC EVALUATIONS. VALIDATING THE MODEL OF WELTE

    Nov 1, 2008, 00:00

  • PCN71 COST-EFFECTIVENESS OF ORALTOPOTECAN PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH RELAPSED SMALL-CELL LUNG CANCER (SCLC) IN THE UK

    Nov 1, 2008, 00:00

  • PG126 DERIVING PREFERENCE BASED UTILITIES FOR CD AND UC PATIENTS- CONVERTING IBDQ INTO EQ-5D UTILITIES

    Nov 1, 2008, 00:00

  • PSY1 A SYSTEMATIC REVIEW OF THE EFFICACY OF RECOMBINANT ACTIVATED FACTORVII (RFVIIA) AND ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (APCC) IN THE ON-DEMANDTREATMENT OF MINOR TO MODERATE BLEEDING EPISODES FOR HAEMOPHILIA PATIENTS WITH INHIBIT ...

    Nov 1, 2008, 00:00

  • PSY43 THE IMPACT OF ROMIPLOSTIM ON PATIENT-REPORTED OUTCOMES MEASURED BY THE EUROQOL (EQ-5D)

    Nov 1, 2008, 00:00

  • PCV10 SUPERIOR FORGIVENESS WITH ALISKIREN IN THE PRESENCE OF IMPERFECT COMPLIANCE

    Nov 1, 2008, 00:00

  • PSS15 SENSITIVE SKINS IN SPAIN- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PSS2 EFFECTIVENESS OF THE RESTOR MULTIFOCAL INTRAOCULAR LENS (IOL) IN CATARACT AND PRESBYOPIA SURGERIES IN TWO EUROPEAN COUNTRIES

    Nov 1, 2008, 00:00

  • PDB62 IMPACT OF INSURANCE PAYMENT SYSTEMS ON QUALITY OF CARE AND HEALTH CARE SERVICE UTILIZATION IN TYPE 2 DIABETES MEDICAID ENROLLEES

    Nov 1, 2008, 00:00

  • PRS23 IS THE EQ-5D RESPONSIVE TO RECOVERY FROM A MODERATE COPD EXACERBATION?

    Nov 1, 2008, 00:00

  • PMC6 SOCIAL DISCOUNTING IN THE ECONOMIC EVALUATION OF HEALTH CARE PROGRAMMES

    Nov 1, 2008, 00:00

  • PCN21 COST-EFFECTIVENESS OF LAPATINIB PLUS CAPECITABINE FORWOMEN WITH HER2 METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH TRATSTUZUMAB IN FINLAND

    Nov 1, 2008, 00:00

  • PDB38 THE COST-EFFECTIVENESS OF GROWTH HORMONE REPLACEMENTTHERAPY WITH GENOTROPIN IN HYPOPITUITARY ADULT PATIENTS

    Nov 1, 2008, 00:00

  • PCV42 COST-EFFECTIVENESS OF POPULATION-BASED STRATEGIES DIRECTED AT ALBUMINURIA

    Nov 1, 2008, 00:00

  • PHP37 HEALTH EXPENDITURES AND PERFORMANCE.THE ANLISIS OF THE FINANCIAL GAPS IN BUENOS AIRES PROVINCE

    Nov 1, 2008, 00:00

  • PCN83 PERFORMANCE AND ADEQUACY OF PATIENT-PERSPECTIVE CRITERIA IN THE ASSESSMENT OF TEST-RETEST RELIABILITY- THE CASE OF THE PERFORM QUESTIONNAIRE

    Nov 1, 2008, 00:00

  • PCV1 THE ROLE OF LDL-LEVELS IN INITIATING STATIN TREATMENT

    Nov 1, 2008, 00:00

  • PHP30 COST DRIVERS IN THE PHARMACEUTICAL MARKET IN GERMANY IN 2007

    Nov 1, 2008, 00:00

  • PG125 ESTABLISHING THE RELATIONSHIP BETWEENTHE ULCERATIVE COLITIS DISEASE ACTIVITY INSTRUMENT (UCDAI) AND PATIENT HEALTH RELATED QUALITY OF LIFE FROM A LARGE RANDOMISED CONTROLLED TRIAL

    Nov 1, 2008, 00:00

  • PCN79 HEALTH STATE PREFERENCE STUDY MAPPING THE CHANGE OVER THE COURSE OF THE DISEASE PROCESS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)

    Nov 1, 2008, 00:00

  • PMH58 BUDGET CONSTRAINTS AS A MAJOR CAUSE FOR UNDERTREATMENT OF PATIENTS SUFFERING FROM ALZHEIMERS DISEASE IN GERMANY- A COMPARATIVE PANEL SURVEY OF GENERAL PRACTIONERS AND NEUROLOGISTS

    Nov 1, 2008, 00:00

  • PMS22 ADALIMUMAB, ETANERCEPT AND INFLIXIMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS-COST EFFECTIVENESS ANALYSIS IN POLISH SETTINGS

    Nov 1, 2008, 00:00

  • PMS47 USING HAQTO ESTIMATE HUI3 AND EQ-5D UTILITY VALUES IN SPANISH RHEUMATOID ARTHRITIS PATIENTS

    Nov 1, 2008, 00:00

  • PSY6 PREDICTING FACTORS FOR METABOLIC SYNDROME FOR US ADOLESCENTS AGE 12-17

    Nov 1, 2008, 00:00

  • PIN15 COST-EFFECTIVENESS OF PALIVIZUMAB IN THE PROPHYLAXIS OF SEVERE BRONCHIOLITIS CAUSED BY RSV- RESULTS OF A DECISION MODEL WITH LOCAL DATA

    Nov 1, 2008, 00:00

  • PCN36 PHARMACOECONOMIC COMPARISON OF TWO PROTOCOLS FACVS. CMF IN THE TREATMENT OF EARLY BREAST CANCER

    Nov 1, 2008, 00:00

  • PHP46 CATEGORISING RESEARCH- WHERE IS THE FOCUS?

    Nov 1, 2008, 00:00

  • MH7 PATIENT REPORTED OBJECTIVES AND PRIORITIES FOR THE TREATMENT OF SCHIZOPHRENIA IN GERMANY- A MIXED METHODS APPROACH TO CAPTURING THE PATIENTS PERSPECTIVE

    Nov 1, 2008, 00:00

  • PDB65 A COMPARISON OF DIABETES KNOWLEDGE AMONG RESIDENTS IN BANGKOK AND OTHER CENTRAL PROVINCES OF THAILAND

    Nov 1, 2008, 00:00

  • PND14 MEDICATION COSTS OF PATIENTS WITH CYSTIC FIBROSIS (CF) IN GERMANY

    Nov 1, 2008, 00:00

  • PIN25 COST-EFFECTIVENESS OF 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV) INCLUDING HERD PROTECTION IN TURKEY

    Nov 1, 2008, 00:00

  • PND6 GLATIRAMER ACETATE VERSUS INTERFERON BETA-1A FOR INTRAMUSCULAR ADMINISTRATION- A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS

    Nov 1, 2008, 00:00

  • PCV47 ECONOMIC EVALUATION OF AN ABDOMINAL AORTIC ANEURYSM SCREENING PROGRAM

    Nov 1, 2008, 00:00

  • PMS69 PATTERNS OF MORBIDITY AND DIRECT COSTS ASSOCIATED IN THE OSTEOPOROSIS SPANISH POPULATION SETTING

    Nov 1, 2008, 00:00

  • PMS25 COST-EFFECTIVENESS OF RITUXIMAB (MABTHERA) COMPARED WITH TNF INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN POLAND

    Nov 1, 2008, 00:00

  • PCN29 ECONOMIC EVALUATION OF SUNITINIB FIRST-LINE FOR METASTATIC RENAL CELL CARCINOMAVERSUS SORAFENIB, TEMSIROLIMUS AND BEVACIZUMAB INTERFERON-ALFA IN THE SWEDISH HEALTH SERVICE SETTING

    Nov 1, 2008, 00:00

  • PHP39 LINKING HOSPITAL ADMISSION DATA INTO PRIMARY CARE RECORDS WITHIN THE GENERAL PRACTICE RESEARCH DATABASE

    Nov 1, 2008, 00:00

  • PIN18 ANALYSIS OF COST-EFFECTIVENESS OF ITRACONAZOLE IN THE TREATMENT OF INVASIVE ASPERGILLOSIS IN TURKISH SETTING

    Nov 1, 2008, 00:00

  • PSY34 COSTS AND PATIENT-REPORTED OUTCOMES (PRO) IN GERMAN PATIENTS WITH CHRONIC KNEE AND HIP PAIN

    Nov 1, 2008, 00:00

  • PCV19 THE TIME OF SUNRISE AND HOURS WITH DAYLIGHT MAY HAVE AN EFFECT ON THE SEASONALITY AND DIURNAL VARIATION OF A HEART ATTACK

    Nov 1, 2008, 00:00

  • PIH9 COST-EFFECTIVENESS OF LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS) FOR THE TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING (DUB) IN SPAIN

    Nov 1, 2008, 00:00

  • PG112 MODELING THE LONG-TERM COST-EFFECTIVENESS OF CRONIC HEP. B THERAPIES IN SPAIN

    Nov 1, 2008, 00:00

  • PDB6 EFFECTS OF PIOGLITAZONE AND ROSIGLITAZONE ON GLUCOSE AND THE CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH TYPE 2 DIABETES- A META-ANALYSIS

    Nov 1, 2008, 00:00

  • PCV3 COMPARISON OF GOAL ATTAINMENT RATES BETWEEN USERS OF SIMVASTATIN 40 MG AND OTHER STATINS

    Nov 1, 2008, 00:00

  • PCV82 CHANGE IN LIPID VALUES, TARGET LIPID VALUE ATTAINMENT, AND ANNUAL HEALTH CARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS INITIATING COMBINATION STATIN AND EXTENDED-RELEASE NIACIN THERAPY

    Nov 1, 2008, 00:00

  • PCV85 STROKE PATIENT RESOURCE USE AND CAREGIVER BURDEN OUTCOMES BY SEVERITY (RECOVERY) STUDY- METHODS AND RESULTS FROM THE ATHENS STROKE REGISTRY

    Nov 1, 2008, 00:00

  • HT4 HEALTH TECHNOLOGY ASSESSMENTS- ARE THEY RELEVANT TO CLINICAL PRACTICE?

    Nov 1, 2008, 00:00

  • PCV115 ASSESSING THE POTENTIAL BENEFITS OF CHANGING REIMBURSEMENT CRITERIA FOR LIPID LOWERINGTHERAPY IN KOREA

    Nov 1, 2008, 00:00

  • PSS8 A TOPIC DERMATITIS IN CHILDHOOD- WHAT 'DERMATOLOGICAL FUTURE' FOR THESE CHILDREN?

    Nov 1, 2008, 00:00

  • PDB37 IS INSULIN GLARGINE A COST-EFFECTIVE OPTION FOR TREATMENT OF PATIENTS NA AND AGE BELOW 65YEARS IN COMPARISON TO NPH AND PREMIX IN POLAND?

    Nov 1, 2008, 00:00

  • AR4 MEASUREMENT AND RATES OF ADHERENCE TO BIOLOGICS IN PATIENTS WITH RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PCV106 PATIENT OUTCOMES AND HEALTH ECONOMICS ASSOCIATED WITH THE USE OF OCTYLCYANOACROLATE TOPICAL SKIN ADHESIVE IN CABG SURGERY

    Nov 1, 2008, 00:00

  • PSS60 DERMATOLOGY LIFE QUALITY INDEX IS MORE SENSITIVE THAN PSORIASIS AREA AND SEVERITY INDEX TO MEASURE TREATMENT EFFECT IN PATIENTS WITH PSORIASIS- FINDINGS FROM THE PHOENIX I TRIAL

    Nov 1, 2008, 00:00

  • PIN41 DEVELOPING AN ECONOMIC MODEL OF GRAM COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI) FOR INPATIENT AND OUTPATIENT TREATMENT SETTINGS

    Nov 1, 2008, 00:00

  • PHC6 COST-EFFECTIVENESS OF RIVAROXABANVERSUS ENOXAPARIN FORTHROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT IN SPAIN

    Nov 1, 2008, 00:00

  • PIN11 COST-EFFECTIVENESS OF QUADRIVALENT HPV VACCINATION IN FINLAND

    Nov 1, 2008, 00:00

  • PIN10 THE ECONOMIC IMPACT OF LOWER HIV PREVALENCE ESTIMATES

    Nov 1, 2008, 00:00

  • PCASE3 USING IN-HOUSE STRATEGIES TO OVERCOME INCONSISTENCIES BETWEEN EXPENDITURES AND BUDGETING

    Nov 1, 2008, 00:00

  • PIN32 COSTS OF INTERMITTENT VERSUS CONTINUOUS ANTIRETROVIRAL THERAPY IN PATIENTS WITH CONTROLLED HIV INFECTION.A SUBSTUDY OF THE ANRS 106 WINDOW TRIAL

    Nov 1, 2008, 00:00

  • PMS68 ANTI-TUMOUR NECROSIS FACTOR- INHIBITOR DOSE CHANGES IN RHEUMATOID ARTHRITIS PATIENTS IN A PROSPECTIVE PATIENT REGISTRY SETTING

    Nov 1, 2008, 00:00

  • PMH35 COST ANALYSIS OF THE TRENDS IN HOSPITALISATION OF PATIENTS WITH SCHIZOPHRENIA IN SPAIN FROM 1980-2004

    Nov 1, 2008, 00:00

  • PG14 BUDGET IMPACT OF METHYLNALTREXONE SC ON A PUBLIC DRUG PROGRAM FORMULARY

    Nov 1, 2008, 00:00

  • PHC9 COST-EFFECTIVENESS OF RIVAROXABANVERSUS ENOXAPARIN FORTHROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT IN THE UK

    Nov 1, 2008, 00:00

  • PCN70 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA WITH THE RITUXIMAB, FLUDARABINE AND CYCLOPHOSPHAMIDE REGIMEN-AN ECONOMIC EVALUATION BASED ON OBSERVATIONAL DATA

    Nov 1, 2008, 00:00

  • PCV32 ECONOMIC EVALUATION OF ATORVASTATIN AND ROSUVASTATIN USING HEAD-TO-HEAD RANDOMIZED CONTROLLED TRIAL WITH UP-TITRATION OF DRUG DOSES TO OBTAIN THERAPEUTIC TARGETS FOR LDL-CHOLESTEROL

    Nov 1, 2008, 00:00

  • PCV70 COST-EFFECTIVENESS OF CLOPIDOGREL IN COMBINATION WITH ASPIRIN FOR ACUTE CORONARY SYNDROMES IN AUSTRALIA

    Nov 1, 2008, 00:00

  • PCV103 TECHNOLOGICAL INNOVATION AND THE DECISION-MAKING PROCESS IN ITALIAN HOSPITALS

    Nov 1, 2008, 00:00

  • PDB67 PATIENT-CENTERED OUTCOMES IN THE ECONOMIC EVALUATION OF TYPE 2 DIABETES TREATMENT- A SYSTEMATIC REVIEW OF MODELING METHODS

    Nov 1, 2008, 00:00

  • PHP13 MARKET AUTHORIZATION (MA) AND REIMBURSEMENT- ANALYSIS OF THE POST-MA TIMELINES AND THE ACCESS TO NEW MEDICINES IN BELGIUM

    Nov 1, 2008, 00:00

  • PIN45 IMPACT OF PATIENT-HEALTH CARE PROVIDER COMMUNICATION- THE HIV/AIDS PATIENTS PERSPECTIVES

    Nov 1, 2008, 00:00

  • PCV95 SOCIODEMOGRAPHIC AND CARDIOVASCULAR RISK FACTORS INFLUENCES ON EQ-5D SOCIAL PREFERENCES SCORES AND SELF-REPORTED HEALTH- A GENERAL POPULATION SURVEY IN ARGENTINA

    Nov 1, 2008, 00:00

  • PMS58 FIBROMYALGIA MOLDOFSKY QUESTIONNAIRE (FMQ)- USE OF A TOOL TO AID DIAGNOSIS

    Nov 1, 2008, 00:00

  • PMC20 QUANTITATIVE APPROACH TO DETERMINE THE EFFECT OF SEGMENTATION ON REVENUE GENERATION, POSITIONING AND PRICING OF PHARMACEUTICALS

    Nov 1, 2008, 00:00

  • PCV8 CLINICAL AND ECONOMIC IMPACT OF DRUG-ELUTING STENT AND BARE METAL STENT IN HONG KONG-A SINGLE CENTRE 'REALWORLD' EXPERIENCE

    Nov 1, 2008, 00:00

  • PIN20 COST-EFFECTIVENESS OF SURGICAL INTERVENTION FOR THERAPY-INDUCED FACIAL LIPOATROPHY IN HIV-INFECTED PATIENTS

    Nov 1, 2008, 00:00

  • PMC5 A MISSING DATATHRESHOLD AS APPLIED TO HEALTH OUTCOMES DATA- DIFFERENTIAL IMPLICATIONS FOR COST-UTILITY ANALYSIS BY DIAGNOSIS

    Nov 1, 2008, 00:00

  • PMS9 PREVALENCE OF FIBROMYALGIA IN PORTUGAL

    Nov 1, 2008, 00:00

  • PCN46 COST-MINIMIZATION ANALYSIS OF CAPECITABINE VERSUS UFT/LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN BRAZIL

    Nov 1, 2008, 00:00

  • PG130 A EUROPEAN CROSS-SECTIONAL STUDY TO EVALUATE SYMPTOM BURDEN AND CLINICAL MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE (RANGE-GREECE)

    Nov 1, 2008, 00:00

  • PND4 GLATIRAMER ACETATE VERSUS INTERFERON BETA-1B FOR SUBCUTANEOUS ADMINISTRATION- A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS

    Nov 1, 2008, 00:00

  • PMS41 COST-EFFECTIVENESS OF CELECOXIB COMPARED TO CONVENTIONAL NSAIDS AND NSAIDPPI COMBINATION THERAPY IN RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PMC58 THE POTENTIAL PENALTY FOR NOT SAMPLING FROM THE RISK SET IN NESTED CASE-CONTROL DESIGNS- EVIDENCE FROM SIMULATED DATA

    Nov 1, 2008, 00:00

  • PMC53 IS UTILITY A LINEAR FUNCTION OF LIFETIME?

    Nov 1, 2008, 00:00

  • PSS25 COST-EFFECTIVENESS OF ETANERCEPT AND EFALIZUMAB IN THE MANAGEMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS

    Nov 1, 2008, 00:00

  • PSY7 THE BUDGETARY IMPACT OF INCLUDING LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING AS A COVERED SURGICAL TREATMENT FOR MORBIDLY OBESE ADULTS IN A MANAGED CARE POPULATION

    Nov 1, 2008, 00:00

  • PSS9 SENSITIVE SCALP- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PHP34 COSTS ASSOCIATED TO ADDITIONAL TEMPORAL SICK LEAVE DAYS IN THE IMSS

    Nov 1, 2008, 00:00

  • PCV67 CLINICAL CHARACTERISTICS, MEDICATION AND COSTS IN ACUTE HEART FAILURE PATIENTS IN THE CZECH REPUBLIC

    Nov 1, 2008, 00:00

  • PCN6 MODELING LUNG AND BREAST CANCER INCIDENCE IN SPAIN- A ZERO INFLATED NEGATIVE BINOMIAL REGRESSION APPROACH

    Nov 1, 2008, 00:00

  • PMS20 IMPACT OF MEDICATION NON-COMPLIANCE AND NON-PERSISTENCE ON PHARMACOECONOMIC EVALUATIONS IN OSTEOPOROSIS

    Nov 1, 2008, 00:00

  • PCV39 COST-EFFECTIVENESS OF NIASPANVERSUS ZETIA AS ADD-ON TREATMENTTO STATIN THERAPY IN HIGH-RISK PATIENTS

    Nov 1, 2008, 00:00

  • IN1 COST EFFECTIVENESS ANALYSIS OF REYATAZ VERSUS KALETRA IN THE TREATMENT OF NAVE HIV PATIENTS IN ITALY

    Nov 1, 2008, 00:00

  • PRS34 QUALITY OF LIFE DURING ACUTE EXACERBATIONS OF COPD- COMPARING EQ-5D, SF-12 AND SGRQ

    Nov 1, 2008, 00:00

  • PCV90 THE CONTRIBUTION OF THE MEASUREMENT OF TREATMENT ACCEPTABILITY TO UNDERSTAND PATIENTS ADHERENCE TO LONG-TERM TREATMENTS. RESULTS FROM A FEASIBILITY STUDY CONDUCTED WITH IN FINE PHARMA- A COMMUNITY-PHARMACY NETWORK DEDICATED TO PHARMAC ...

    Nov 1, 2008, 00:00

  • PMH27 HEALTH SERVICE EXPENDITURES FOR PATIENTS WITH A DIAGNOSIS OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY-AN AGE AND GENDER SPECIFIC ANALYSIS

    Nov 1, 2008, 00:00

  • PCV31 ORAL ANTICOAGULATION AFTER MAJOR HIP OR KNEE REPLACEMENT SURGERIES

    Nov 1, 2008, 00:00

  • PIN1 A BAYESIAN META-ANALYSIS OF THE EFFICACY OF SIX ANTIMICROBIAL AGENTS FOR CONFIRMED STAPHYLOCOCCUS AUREUS COMPLICATED SKIN AND SOFT-TISSUE INFECTIONS (CSSTIS)

    Nov 1, 2008, 00:00

  • CN8 AN ECONOMIC EVALUATION OF DASATINIB (SPRYCEL) IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN CENTRAL AND EASTERN EUROPE

    Nov 1, 2008, 00:00

  • PCN73 DEVELOPING A COMPREHENSIVE COSTS TOOLKIT TO FACILITATE ECONOMIC EVALUATIONS OF CANCER CARE IN FRANCE

    Nov 1, 2008, 00:00

  • PCV17 COLD AND INACTIVITY- THE ULTIMATE FACTORS FOR HEART ATTACK

    Nov 1, 2008, 00:00

  • PMC16 EXPENSIVE DRUGS FOR RARE DISORDERS AND THE LOGIC OF COST-EFFECTIVENESS

    Nov 1, 2008, 00:00

  • PCV26 TREATING TO LOWER LDL-C TARGETS- ESTIMATING THE NUMBER AND COST OF CARDIOVASCULAR EVENTS AVOIDED FOR REGIONAL HEALTH ECONOMIES IN ENGLAND, SCOTLAND, WALES AND NORTHERN IRELAND

    Nov 1, 2008, 00:00

  • PSS54 EVALUATION OF TREATMENT SATISFACTION WITH ETANERCEPT VERSUS ALTERNATIVE TREATMENTS FOR PSORIASIS- A PATIENT SURVEY ACROSS NINE EUROPEAN COUNTRIES

    Nov 1, 2008, 00:00

  • PDB47 THE SUITABILITY OF POLYCYSTIC OVARY SYNDROME-SPECIFIC QUESTIONNAIRES FOR MEASURING THE IMPACT OF PCOS ON QUALITY OF LIFE IN CLINICAL TRIALS

    Nov 1, 2008, 00:00

  • CV2 A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH A TRIAL FIBRILLATION-AF-QOL

    Nov 1, 2008, 00:00

  • PRS36 WILLINGNESS TO PAY FOR CAREGIVERS OF PEDIATRIC ASTHMATIC PATIENTS IN KOREA

    Nov 1, 2008, 00:00

  • PSS47 A TOPIC DERMATITIS AND THERMAL THERAPY- EVALUATION IN CHILDREN UNDER 15

    Nov 1, 2008, 00:00

  • PCN16 ANALYSIS OF COSTS AND CONSEQUENCES IN CANCER PATIENTS RECEIVING CAPECITABINE

    Nov 1, 2008, 00:00

  • PHP1 PATIENTS PREFERENCES FOR AND PRICE ELASTICITY OF GENERIC AND BRANDED OVER-THE-COUNTER MEDICINES-AN ADAPTIVE CONJOINT ANALYSIS (ACA) APPROACH

    Nov 1, 2008, 00:00

  • CASE2 DOTECHNOLOGY EVALUATIONS BASED ON EVIDENCE FROM CONDITIONAL FUNDING LEAD TO AN INCREASE IN POLICY FORMATION?- FINDINGS FROM, AND IMPLICATIONS OF, ONTARIOS EVIDENCE-BASED HTA PROCESS

    Nov 1, 2008, 00:00

  • PCV52 COST-UTILITY ANALYSIS OF HOMETELEMONITORING IN ELDERLY PATIENTS WITH CHRONIC HEART FAILURE

    Nov 1, 2008, 00:00

  • PCV16 MONITORING POTENTIAL DRUG-DRUG INTERACTIONS-AN APPLICATION FOR PRESCRIPTION CLAIMS DATABASES

    Nov 1, 2008, 00:00

  • PMC26 PREDICTING HEALTH SERVICE UTILIZATION WITH THE PCS AND MCS OF THE SF-36

    Nov 1, 2008, 00:00

  • PMS26 COST-EFFECTIVENESS ANALYSIS OF RHBMP-2 IN THE TREATMENT OF OPENTIBIA FRACTURES IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PMS63 PATIENT REPORTED OUTCOMES OF DIFFERENT SURGICAL PROCEDURES IN PATIENTS WITH CARTILAGE DEFECTS OF THE KNEE AFTER 1 TO 5YEARS

    Nov 1, 2008, 00:00

  • PMS29 COSTS AVOIDED BY DIAGNOSING FIBROMYALGIA IN SPANISH PATIENTS

    Nov 1, 2008, 00:00

  • PMH56 PATTERNS OF FIRST VISITS TO PSYCHIATRIC CLINICS IN TAIWAN- A NATIONWIDE STUDY, 2006

    Nov 1, 2008, 00:00

  • PCV116 THE ANALYSIS OF STATINS USAGE IN CROATIA DURING THE FIVE-YEAR PERIOD

    Nov 1, 2008, 00:00

  • PCN45 ECONOMIC ANALYSIS OF THE CLINICAL OUTCOMES OF SURGICAL THERAPY (COST) TRIAL COMPARING LAPAROSCOPICALLY-ASSISTED COLECTOMY (LAC) WITH OPEN COLECTOMY (OC) FOR COLON CANCER

    Nov 1, 2008, 00:00

  • PSS34 MODELLING THE LONG-TERM CLINICAL OUTCOMES OF MEDICAL MANAGEMENT OF PRIMARY OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION

    Nov 1, 2008, 00:00

  • PCN60 CLINICAL AND ECONOMIC ASPECTS OF THE MANAGEMENT OF PATIENTS WITH MALIGNANT ASCITES-RESULTS OF A PILOT STUDY

    Nov 1, 2008, 00:00

  • PIN27 COST-EFFECTIVENESS ANALYSIS OF CASPOFUNGIN VERSUS AMPHOTERICIN B, VORICONAZOLE, AND ANIDULAFUNGIN IN THE TREATMENT OF INVASIVE CANDIDIASIS

    Nov 1, 2008, 00:00

  • PMC14 A FRAMEWORK FOR REAL-WORLD ECONOMIC EVALUATION BY INCORPORATING IMPLEMENTATION PARAMETERS

    Nov 1, 2008, 00:00

  • PSS14 DRY SKIN- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PHC3 COST AND QUALITY IMPROVEMENTS ASSOCIATED WITH MINIMALLY INVASIVE SURGERY (MIS) TOTAL HIP ARTHROPLASTY (THA)

    Nov 1, 2008, 00:00

  • PCN62 ECONOMIC BURDEN OF TOXICITIES ASSOCIATED WITH SALVAGE TREATMENT IN ADVANCED AND METASTATIC BREAST CANCER

    Nov 1, 2008, 00:00

  • PND26 ARE THERE DIFFERENCES IN PATIENT SATISFACTION WITH INSOMNIA MEDICATIONS? PILOT RESULTS FROM A NOVEL REGISTRY

    Nov 1, 2008, 00:00

  • PIN54 ADAPTATION CALIBRATION OF A UK MODEL OF MENINGOCOCCAL DISEASE TO THE US SETTING

    Nov 1, 2008, 00:00

  • PSY26 COST OF TYROSINAEMIA TYPE ONE IN POLAND IN 2006

    Nov 1, 2008, 00:00

  • MS4 GOLIMUMAB SIGNIFICANTLY IMPROVES PRODUCTIVITY IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS- RESULTS FROM THE PHASE 3 GO-RAISE STUDY

    Nov 1, 2008, 00:00

  • PMC51 UTILITIES OF THE EQ-5D-TRANSFERABLE OR NOT? INFLUENCE OF THE NATIONAL VALUE SETS OF THE EQ-5D ON THE INCREMENTAL UTILITIES OF TWO HEALTH STATES

    Nov 1, 2008, 00:00

  • PRS13 THE COST-EFFECTIVENESS OF VARENICLINE IN SMOKING CESSATION IN DENMARK

    Nov 1, 2008, 00:00

  • PMS53 PUBLIC HEALTH OBJECTIVE- THE QUALITY OF LIFE OF SUFFERERS OF OSTEOARTHRITIS FINALLY TAKEN INTO CONSIDERATION

    Nov 1, 2008, 00:00

  • MD3 COST-EFFECTIVENESS OF LUMBAR DISC ARTHROPLASTY VERSUS LUMBAR FUSION FROM A HEALTH CARE SYSTEMS PERSPECTIVE IN AUSTRIA

    Nov 1, 2008, 00:00

  • PSY38 IMPACT OF TENSION HEADACHE ON WORK PRODUCTIVITY LOSS AND ACTIVITY IMPAIRMENT

    Nov 1, 2008, 00:00

  • PMH7 PREVALENCE OF POTENTIAL MEDICATION INTERACTIONS WITH ANTIPSYCHOTICS VIA CYTOCHROME P450 IN PATIENTS WITH SCHIZOPHRENIA IN GERMANY

    Nov 1, 2008, 00:00

  • PIN9 BUDGET IMPACT ANALYSIS OF INTRODUCING ROUTINE VACCINATION WITH A QUADRIVALENT HPV-VACCINE IN NORWAY

    Nov 1, 2008, 00:00

  • PG134 PATIENT PREFERENCES FOR CROHNS DISEASE MAINTENANCE THERAPY- A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2008, 00:00

  • PG119 THE COST-UTILITY OF LIVER DISEASE DIAGNOSIS- ASSESSING GP DECISIONS FOR PATIENTS WITH ABNORMAL LIVER FUNCTION TESTS AND NO OBVIOUS LIVER DISEASE

    Nov 1, 2008, 00:00

  • PMC28 STATUS-QUO BIAS IN STATED-CHOICE STUDIES- IS IT REAL?

    Nov 1, 2008, 00:00

  • PG116 DIRECT MEDICAL COSTS OF GERD AND ASSOCIATED FACTORS

    Nov 1, 2008, 00:00

  • PSS27 COST-EFFECTIVENESS OF THREE INTRA-OCULAR LENSES AFTER CATARACT SURGERY IN THE NETHERLANDS- RESTOR, ARRAY-SA40 AND A MONOFOCAL

    Nov 1, 2008, 00:00

  • PSY50 ASSESSING THE VALUE OF 24-HOUR CHRONIC PAIN CONTROL FROM THE PATIENT PERSPECTIVE- DO EXISTING PATIENT-REPORTED OUTCOMES INSTRUMENTS ADEQUATELY COVER THE RELEVANT CONCEPTS RELATED TO 24-HOUR CHRONIC PAIN CONTROL?

    Nov 1, 2008, 00:00

  • PCV87 PERSISTENCE WITH AMIODARONE OR SOTALOL AND ITS IMPACT ON A TRIAL FIBRILLATION-RELATED HOSPITALIZATIONS AND CARDIOVERSIONS

    Nov 1, 2008, 00:00

  • PMC19 COST-EFFECTIVENESS ANALYSES OF BEHAVIORAL INTERVENTIONS- TOWARDS A MORE REALISTIC COST-EFFECTIVENESS RATIO BY INCLUDING INTERMEDIATE OUTCOME MEASURES

    Nov 1, 2008, 00:00

  • PMH2 DIRECT AND INDIRECT TREATMENT EFFECTS ON SLEEP DISTURBANCE IN GENERALIZED ANXIETY DISORDER- A STATISTICAL MEDIATION MODEL ANALYSIS

    Nov 1, 2008, 00:00

  • PIH18 RELIABILITY, AND VALIDITY OF THE FATIGUE SYMPTOM INVENTORY

    Nov 1, 2008, 00:00

  • PMC48 UPDATE OF TRENDS IN THE INCLUSION OF PATIENT-REPORTED OUTCOME (PRO) DATA IN APPROVED DRUGS LABELING BY FDA AND EMEA

    Nov 1, 2008, 00:00

  • PRS37 RACIAL DISPARITIES IN UTILIZATION OF ASTHMA CONTROLLER DRUGTHERAPY

    Nov 1, 2008, 00:00

  • PHP57 INAPPROPRIATE SEDATION IN ICUS- EVIDENCE FROM THE LITERATURE

    Nov 1, 2008, 00:00

  • PHP45 THE REIMBURSEMENT OF ORPHAN DRUGS ACROSS EUROPE

    Nov 1, 2008, 00:00

  • PIN14 USING A DECISION SIMULATION MODELTO EVALUATE THE COST-EFFECTIVENESS OF THE TREATMENT OF NUCLEOSIDE-NAVE HBE-ANTIGEN NEGATIVE CHB PATIENTS IN ITALY WITH ENTECAVIR AND TEN OF OVIR

    Nov 1, 2008, 00:00

  • PCN64 SHIFT OF PUBLIC HEALTH CARE EXPENDITURES FOR PALLIATIVE CANCER PATIENTS FROM INPATIENT TO OUTPATIENT EFFECTED BY HOME CARE SUPPORT TEAMS PROVIDED BY A UNIVERSITY HOSPITAL IN AUSTRIA

    Nov 1, 2008, 00:00

  • PSY4 EPIDEMIOLOGY OF IDIOPATHICTHROMBOCYTOPENIC PURPURA IN BELGIUM ASSESSED USING HOSPITAL RECORDS

    Nov 1, 2008, 00:00

  • PHC1 TREATMENT OF DISCOGENIC LOW BACK PAIN WITH INTRADISCAL ELECTROTHERMAL THERAPY [IDET], A MINIMALLY INVASIVE, LOW COST ALTERNATIVE TO OPEN SURGERY- A PROSPECTIVE 24-MONTH OUTCOMES STUDY IN 50 CONSECUTIVE PATIENTS

    Nov 1, 2008, 00:00

  • PHP55 CHIRALTY AND HOSPITAL FORMULARY- A SECOND LIFE FOR A BLOCKBUSTER

    Nov 1, 2008, 00:00

  • PCN103 HETEROGENEITY IN THE APPROACH TAKEN TO CONDUCTING CHART AUDITS IN AUSTRALIAN HOSPITALS

    Nov 1, 2008, 00:00

  • PSS23 TOPICAL TACROLIMUS FOR THE TREATMENT OF A TOPIC DERMATITIS- A SYSTEMATIC REVIEW WITH META-ANALYSES

    Nov 1, 2008, 00:00

  • PHP17 SOURCES OF INFORMATION ON DRUGS USED BY GENERAL PRACTITIONERS IN POLAND

    Nov 1, 2008, 00:00

  • PHP25 EVALUATING AN ONLINE FREEWARE CALCULATOR AND PLOTTER FOR ANALYZING COST EFFECTIVENESS DATA FOR FORMULARY DRUG CLASSES

    Nov 1, 2008, 00:00

  • CV4 COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN STABLE ANGINA PATIENTS IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PCN54 HOSPITAL BURDEN OF DISEASE ASSOCIATED WITH METASTATIC BONE DISEASE (MBD) AND SKELETAL-RELATED EVENTS (SRES) IN PATIENTS WITH BREAST CANCER (BC) AND PROSTATE CANCER (PC) IN THE UNITED KINGDOM (UK)

    Nov 1, 2008, 00:00

  • PMC49 COMPARISON OF HEALTH LOCUS OF CONTROL BETWEEN PHYSICIANS AND THE GENERAL PUBLIC- MULTI-GROUP STRUCTURAL EQUATION MODELING

    Nov 1, 2008, 00:00

  • PCN40 COST-EFFECTIVENESS OF TREATMENT WITH TRASTUZUMAB IN PATIENTS WITH EARLY BREAST CANCER FROM THE PORTUGUESE SOCIETAL PERSPECTIVE

    Nov 1, 2008, 00:00

  • PHC10 PROPHYLAXIS WITH RIVAROXABAN AGAINST VENOUS THROMBOEMBOLISM (VTE)-A COST-CONSEQUENCE ANALYSIS FROM THE PERSPECTIVE OF THE ITALIAN HEALTH CARE SERVICE

    Nov 1, 2008, 00:00

  • PMC33 THE ROLE OF RANKING DATA IN HEALTHVALUATION

    Nov 1, 2008, 00:00

  • PSY59 A POPULATION STUDY ON THE AGE-SPECIFIC RELATIONSHIP BETWEEN BODY MASS INDEX, METABOLIC DISORDERS, AND UTILIZATION OF AMBULATORY SERVICES

    Nov 1, 2008, 00:00

  • PDB16 THE COST-UTILITY AND BUDGET IMPACT ANALYSIS OF SITAGLIPTIN (JANUVIA) IN TYPE 2 DIABETES IN POLAND

    Nov 1, 2008, 00:00

  • PDB22 COST-EFFECTIVENESS OF INSULIN GLARGINE COMPARED TO INSULIN DETEMIR FOR TYPE 1 (T1DM) AND TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE CANADIAN PAYER SETTING

    Nov 1, 2008, 00:00

  • PCN19 COST EFFECTIVENESS OF CETUXIMAB IN FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER- A MODELLING APPROACH FOR THE UK

    Nov 1, 2008, 00:00

  • PSY46 PATIENT-REPORTED OUTCOMES (PRO) AND ECONOMICS OF MIGRAINE IN GERMANY

    Nov 1, 2008, 00:00

  • PDB20 LONG-TERM COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN IN PATIENTS WITH TYPE 1 DIABETES USING A BASAL-BOLUS REGIMEN IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN

    Nov 1, 2008, 00:00

  • PRS1 SMOKING, ASTHMA AND COPD IN ADULTS- A TOO FREQUENT RELATION

    Nov 1, 2008, 00:00

  • PMC21 ASSESSING THE RELATIONSHIP BETWEEN COMPUTATIONAL SPEED AND PRECISION- A CASE STUDY USING A DISCRETE EVENT SIMULATION MODEL IN DIABETES CARE

    Nov 1, 2008, 00:00
  • «
  • 151
  • 152
  • 153
  • 154 (current)
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • »